The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
HOME > COMMENTARY
COMMENTARY
- SURVEY／DPP-4 Inhibitors May Decrease Consumption of SUs
December 1, 2008
- COMMENTARY／Thinking about Why Megapharmas Are Closing Research Labs in Japan
November 24, 2008
- COMMENTARY／Marriage of Nos. 1 and 2 Wholesalers Creates Sensation in Market
November 3, 2008
- COMMENTARY／Competition Intensifies for Development of DPP-4 Inhibitors
September 22, 2008
- COMMENTARY／Yamato Searches for a Way to Start Generics Distribution Business
September 22, 2008
- COMMENTARY／Reform of Ethical Drug Distribution Practices
September 1, 2008
- COMMENTARY／Gov't to Cut Social Security Spending by \220 Bil by Promoting Use of Generics
August 25, 2008
- COMMENTARY／Development Race for RNAi Therapeutics Heating Up in Japan
August 4, 2008
- COMMENTARY 4 articles
July 28, 2008
- COMMENTARY／Industry Needs More Creative Thinking: NHI Pricing System Reform
July 21, 2008
- COMMENTARY／Will Fiscal Rehabilitation Policy Be Maintained?
July 7, 2008
- COMMENTARY／Daiichi Sankyo Surprises the World by Announcing Acquisition of Ranbaxy
June 30, 2008
- Pharmaceutical Partnerships in Japan for Regulatory and Commercial Success
June 30, 2008
- COMMENTARY 4 articles
June 9, 2008
- COMMENTARY／Shaking Pharmaceutical Administration System
May 19, 2008
- COMMENTARY／Personnel Strategy -New Graduates or Work-Ready MRs?
April 21, 2008
- COMMENTARY／Industry-Academia Cooperation Essential for Practical Use of iPS Cells
April 21, 2008
- COMMENTARY／Improvement of Drug Distribution Business Practices Goes into Crucial Stretch
April 14, 2008
- COMMENTARY／Mr Kodama Owes His Sweeping Victory to Members' Desire for Change: JPA
March 31, 2008
- COMMENTARY／Most Mainstay Products Avoid Deep Price Cuts in FY2008 NHI Price Revision
March 31, 2008
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…